GHENT, Belgium, May 2, 2026
MRM Health announced the initiation of its Phase 2b STARFISH-UC clinical trial (NCT07296315) evaluating MH002, an optimized live biotherapeutic product (LBP), in patients with mild-to-moderate ulcerative colitis (UC). The study aims to address a critical gap in inflammatory bowel disease treatment by leveraging microbiome-based therapeutics designed to restore gut balance and reduce inflammation. Approximately 204 patients will be enrolled across clinical sites in Europe and the United States, with topline results expected in Q4 2027, positioning this program as a key milestone in advancing microbiome-driven therapies toward late-stage development.
Advanced Trial Design Targets Clinical Efficacy
The STARFISH-UC study is structured with a 12-week induction phase, comparing two dosing regimens of MH002 versus placebo, followed by a 40-week open-label extension phase to evaluate long-term safety and sustained efficacy. This design enables a comprehensive assessment of both short-term clinical response and durability of treatment benefit, which are critical factors in ulcerative colitis management.
By incorporating multiple dosing strategies, MRM Health aims to identify the optimal therapeutic window for MH002, increasing the probability of success in future pivotal Phase 3 trials. The trial also reflects a growing industry shift toward precision microbiome therapies, where defined microbial consortia are engineered for targeted disease modulation rather than broad-spectrum approaches.
Microbiome Innovation Through CORAL® Platform
Advertisement
At the core of MH002’s development is MRM Health’s proprietary CORAL® platform, which enables the design and scalable manufacturing of disease-specific microbial consortia. Unlike traditional probiotics, MH002 is a next-generation live biotherapeutic composed of carefully selected bacterial strains that work synergistically to modulate immune response, enhance gut barrier integrity, and reduce inflammation. This approach directly targets the underlying pathophysiology of ulcerative colitis, rather than just managing symptoms.
The ability to engineer and standardize complex microbiome compositions represents a significant technological advancement, addressing one of the key challenges in microbiome therapeutics—consistency and reproducibility at scale. As regulatory pathways for LBPs continue to evolve, platforms like CORAL® position companies to bridge the gap between early innovation and commercial viability.
Expanding Pipeline and Strategic Growth Momentum
MRM Health is not limiting its ambitions to ulcerative colitis. In addition to advancing MH002, the company is exploring applications in pouchitis, other inflammatory diseases, and immune-oncology, reflecting the broad potential of microbiome-based interventions. The company’s momentum is further supported by a €55 million Series B funding round completed in September 2025, led by Biocodex with participation from ATHOS, BNP Paribas Fortis Private Equity, and other strategic investors.
This funding provides the financial runway to scale clinical development, expand pipeline programs, and strengthen manufacturing capabilities. The upcoming presentation at the Digestive Disease Week 2026 in Chicago will showcase early clinical insights from MH002, offering the scientific community a preview of how initial data is shaping the design of this confirmatory trial.
Addressing Unmet Needs in Ulcerative Colitis
Ulcerative colitis remains a chronic, relapsing inflammatory condition with significant unmet medical needs, particularly for patients who do not respond adequately to existing therapies. Current treatment options, including biologics and immunosuppressants, often come with variable efficacy, safety concerns, and high costs, leaving room for alternative approaches.
MH002’s microbiome-based mechanism offers a potentially safer and more sustainable solution by restoring natural gut homeostasis rather than suppressing the immune system broadly. If successful, this therapy could redefine treatment paradigms by introducing a disease-modifying, microbiome-driven strategy that complements or even replaces conventional therapies in certain patient populations.
MRM Health’s Phase 2b trial represents a critical inflection point for the microbiome therapeutics field, where scientific promise must translate into robust clinical outcomes. While the approach is innovative, execution risk remains—microbiome therapies have historically struggled with clinical variability and regulatory complexity. However, with a well-structured trial design, strong funding, and a differentiated technology platform, MRM Health is positioning itself as a serious contender in next-generation gastrointestinal therapeutics.
Source: MRM Health press release
